AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States.
Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy.
The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.
Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Country | IE |
IPO Date | Jun 7, 1996 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 154 |
CEO | Gregory J. Divis Jr. |
Contact Details
Address: 10 Earlsfort Terrace Dublin, IE | |
Website | https://www.avadel.com |
Stock Details
Ticker Symbol | AVDL |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001012477 |
CUSIP Number | 05337M104 |
ISIN Number | US05337M1045 |
Employer ID | 00-0000000 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Gregory J. Divis Jr. | Chief Executive Officer & Director |
Thomas S. McHugh | Senior Vice President, Principal Financial and Accounting Officer & Chief Financial Officer |
Angie Woods | Vice President of People & Culture |
Dr. Jason M. Vaughn | Senior Vice President of Technical Operations |
Dr. Jordan S. Dubow M.D. | Consultant |
Gregory J. Davis | Vice President of Corporate and Business Development |
Jennifer Gudeman PharmD | Senior Vice President of Medical & Clinical Affairs |
Jerad G. Seurer | General Counsel & Company Secretary |
Mark W. Elrod | Vice President of Sales |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 14, 2025 | 4 | Filing |
Jan 14, 2025 | 4 | Filing |
Jan 08, 2025 | 8-K | Current Report |
Dec 27, 2024 | 4 | Filing |
Dec 19, 2024 | 4 | Filing |
Dec 16, 2024 | 4 | Filing |
Dec 12, 2024 | 4 | Filing |
Dec 10, 2024 | 4 | Filing |
Dec 10, 2024 | 4 | Filing |
Dec 10, 2024 | 4 | Filing |